Clinuvel Files NEURACTHEL® Instant Dossier With EU Regulators
CUVL is trading near its 52-week low of $4.88 (1.8% above the low).
Summary
Clinuvel filed its NEURACTHEL® Instant (tetracosactide) marketing-authorisation dossier through Europe's decentralised procedure, targeting up to three EU member states. The product is unapproved anywhere, and the review is expected to take 300 days plus clock stops, with first feedback in around four months.
Key Events · Product Development and Regulatory · CUVL
-
EU Dossier Filed for NEURACTHEL® Instant
Clinuvel submitted a marketing-authorisation dossier for NEURACTHEL® Instant (tetracosactide), a branded generic synthetic ACTH analogue, via the European decentralised procedure covering up to three initial EU member states.
-
US$1.3B ACTH Market Targeted
The company estimates the global ACTH market at US$1.3 billion annually and chose launch markets on ACTH usage, prescriber demand, pricing infrastructure and reported shortages, plus overlap with existing SCENESSE® distribution.
-
300-Day Review, Feedback in ~4 Months
After dossier validation, the DCP is intended to take 300 days excluding clock stops, with a final position at day 270; management expects first formal feedback in around four months.
-
No Approval Anywhere Yet
NEURACTHEL® Instant is not currently approved in any country; UK MHRA and additional EU filings are under evaluation, and the US FDA timeline is under review.
Analysis · CUVL · Unknown
Clinuvel has submitted its second pharmaceutical product, NEURACTHEL® Instant, for marketing authorisation in up to three EU member states — the first regulatory filing for a tetracosactide product aimed at a global ACTH market the company sizes at US$1.3 billion a year. Nothing is approved yet, and the decentralised procedure runs 300 review days plus clock stops, with first formal feedback only expected in about four months; this is a pipeline milestone, not revenue. What matters is that it is the first concrete step toward a second commercial product alongside SCENESSE®, and the company says it picked launch markets where existing SCENESSE® distribution can be reused — meaning incremental revenue would come with limited new commercial spend if approval lands.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUVL was trading at $4.97 on NASDAQ in the Unknown sector, with a market capitalization of approximately $260M. The 52-week trading range was $4.88 to $8.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.